NEW YORK (TheStreet
) -- The significant stock market decline of the past two sessions has the five major equity averages on the cusp of ending the week with negative weekly chart profiles. Such will confirm the May 20/May 22 highs as cycle highs. Only the Nasdaq
may end the week with still overbought momentum.
The S&P 500 will have a negative weekly chart profile given a close today below its five-week modified moving average at 1614.15. My semiannual value level is 1566.9 with a monthly pivot at 1602.8 and the May 22 all-time high at 1687.18. The S&P ended Thursday up 11.4% year to date and 5.9% off the high.
In this environment individual stocks could be volatile as traders and investors react to stock specific news.
Today I profile five of the key stocks in the news this morning:
Archer Daniels Midland ($32.61) is now engaged in discussions regarding sale of its cocoa business. The stock ended Thursday below its 50-day simple moving average at $33.36 with its 200-day simple moving average at $30.02 and opened higher this morning but still between these key moving averages. Archer Daniels has a hold rating according to ValuEngine with a semiannual value level at $28.29 and weekly risky level at $34.91.
General Electric ($23.25) reported that its health care unit will acquire certain assets of Ravence. The stock ended Thursday just above its 50-day SMA at $23.08 with its 200-day SMA at $22.33 and opened higher this morning, but is below its 21-day SMA at $23.63. GE has been downgraded to hold from buy this morning according to ValuEngine with a monthly value level at $21.90 and weekly risky level at $24.67.
Medtronic ($51.19) announced an 80 million share repurchase plan this morning. The stock ended Thursday above its 50-day SMA at $49.55 with its 200-day SMA at $45.26 and opened higher but below its 21-day SMA at $51.93. The stock has recently been downgraded to hold from buy according to ValuEngine with a monthly value level at $48.42 and weekly risky level at $54.71.
Oracle ($33.21) reported disappointing quarterly results after the close on Thursday, but also announced that they will raise its dividend by 100%, and will implement a $12 billion share buyback program. The company will also shift its listing to the NYSE from the Nasdaq. The stock ended Thursday just above its 200-day SMA at $33.13, but opened below my annual value level, now a pivot at $30.81. The stock has recently been downgraded to hold from buy according to ValuEngine with a quarterly value level at $27.81, an annual pivot at $30.81, a semiannual pivot at $31.89 and annual risky level at $34.68.
Teva Pharmaceutical ($38.88) received FDA approval for its Plan B One-Step for use without prescription. The stock ended Thursday just below its 50-day and 200-day SMAs at $38.92 and $39.29, and was little changed at today's open. The stock has had a buy rating according to ValuEngine for more than a year. My monthly value level is $35.89 with a weekly risky level at $40.18.
At the time of publication the author held no positions in any of the stocks mentioned.
This article is commentary by an independent contributor, separate from TheStreet's regular news coverage.
EXCLUSIVE OFFER: See inside Jim Cramer’s multi-million dollar charitable trust portfolio to see the stocks he thinks could be potentially HUGE winners. Click here to see his holdings for FREE.
- Stocks & Offerings